Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA) from its SEC filings: 2025 revenue $67.5 million (+25% vs the year before), net margin -413%, free cash flow -$70.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $67.5 million |
| Revenue growth | +25% |
| Net income | -$278.7 million |
| Net margin | -412.9% |
| Free cash flow | -$70.7 million |
| Diluted EPS | $-3.18 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +36% |
| Cash | $70.2 million |
| Long-term debt | $5.6 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.